Mylan Inc. announced that it has entered into a definitive agreement with Abbott Laboratories whereby Mylan Inc. will acquire Abbott Laboratories' non US developed markets specialty and branded generics business in an all-stock transaction. Upon closing, Abbott Laboratories will receive 105 million shares of the combined company worth approximately USD 5.3 billion based on Mylan Inc.’s closing price of USD 50.20 on Friday, July 11, 2014, representing an approximately 21% ownership stake. Pestalozzi represented Mylan Inc. in the Swiss legal aspect of this transaction.